跳至主要内容
临床试验/JPRN-UMIN000004550
JPRN-UMIN000004550已完成3 期

RANDOMIZED PHASE III CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY - GOG-0263

RG Oncology0 个研究点目标入组 360 人开始时间: 2010年11月12日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) Patients with tumor in the parametria, pelvic lymph nodes or any other extra uterine site or with positive surgical margins. 2) Patients with septicemia or severe infection. 3) Patients with intestinal obstruction or gastrointestinal bleeding. 4) Patients with postoperative fistula. 5) Patients with cervix cancer who have received any previous radiation or chemotherapy. 6) Patients whose circumstances do not permit completion of the study or the required follow-up. 7) Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc). 8) Patients with GOG Performance Status of 3 or 4. 9) Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.

研究者

发起方
RG Oncology

相似试验